Alzheimer's Disease Stocks
Biotechnology and diagnostic entities in this sector target the massive, unmet medical need for neurodegenerative therapies by developing small molecules, monoclonal antibodies, and gene therapies designed to modify disease progression or manage debilitating neuropsychiatric symptoms.
As of Oct 23, 2026, Alzheimer's Disease has 35 US-listed companies worth $1.2T combined. The median member moved +0.6% over the past week; ALMR led among the 25 largest at +21.4% and NMRA trailed at -19.9%.
Companies in Alzheimer's Disease
- LLY – Eli Lilly and Company, $1.1T
- BIIB – Biogen Inc, $37B
- AXSM – Axsome Therapeutics Inc, $7.6B
- ACAD – ACADIA Pharmaceuticals Inc, $3.5B
- DNLI – Denali Therapeutics Inc, $3B
- ALMR – Alamar Biosciences, Inc. Common Stock, $2B
- KRSA – Korsana Biosciences, Inc., $1.5B
- MPLT – MapLight Therapeutics, Inc. Common Stock, $458M
- PRTA – Prothena Corporation plc, $435M
- ACIU – AC Immune Ltd, $256M
- LXEO – Lexeo Therapeutics, Inc. Common Stock, $217M
- ALEC – Alector Inc, $214M
- ACOG – Alpha Cognition Inc, $192M
- QTRX – Quanterix Corp, $163M
- TLSA – Tiziana Life Sciences Ltd, $144M
- ABOS – Acumen Pharmaceuticals Inc, $143M
- AVXL – Anavex Life Sciences Corp, $121M
- VYGR – Voyager Therapeutics Inc, $117M
- NMRA – Neumora Therapeutics, Inc., $89.4M
- CGTX – Cognition Therapeutics Inc, $89.1M
- PMN – ProMIS Neurosciences Inc., $74.3M
- INMB – INmune Bio Inc, $53.6M
- ANVS – Annovis Bio Inc, $42.3M
- IGC – India Globalization Capital Inc, $25.4M
- BIVI – Biovie Inc, $11.9M
- NKGN – NKGen Biotech, Inc. Common Stock, $7.8M
- INM – InMed Pharmaceuticals Inc, $7.6M
- ALZN – Alzamend Neuro Inc, $6.5M
- NRSN – Neurosense Therapeutics Ltd, $5.8M
- LGVN – Longeveron LLC, $5.1M
- NIKI – Niki BioSolutions, Inc., $3.7M
- JUNS – Jupiter Neurosciences, Inc. Common Stock, $3.4M
- VCNX – Vaccinex Inc, $2.8M
- SILO – Silo Pharma Inc, $2.5M
- VAXX – Vaxxinity Inc, $12,678